Table 5. Nitric oxide pathway in PAH—summary of clinical studies.
| Drug | Study | Background | Primary endpoint | Secondary endpoints | Duration (weeks) | Patients |
|---|---|---|---|---|---|---|
| Sildenafil (Revatio) | SUPER-1 | None | 6MWD | TTCW | 12 | 227 |
| PACES | Epoprostenol | 6MWD | TTCW | 16 | 264 | |
| Iversen, et al. | Bosentan | 6MWD | – | 12 | 20 | |
| Sastry, et al. | None | TT | – | 12 | 22 | |
| Singh, et al. | None | 6MWD | – | 6 | 20 | |
| Tadalafil (Adcirca) | PHIRST | None | 6MWD | TTCW | 16 | 405 |
| Soluble guanylate cyclase stimulators | ||||||
| Riociguat (Adempas) | PATENT | None, bosentan, prostanoids | 6MWD | TTCW | 12 | 443 |
| CHEST | None, bosentan, prostanoids | 6MWD | TTCW | 12 | – | |
PAH, pulmonary arterial hypertension; 6MWD, 6-minute walk distance.